Fosgemcitabine palabenamide

N/A

Report date: 2022/12/07 17:07:59
NME

Base Information

Drug NameFosgemcitabine palabenamide
Drug Alias NameGemcitabine-ProTideGemzar ProTide - NuCanaGemcitabine analog - NucanaGemcitabine-phosphoramidateCPF-31 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionPyrimidines antagonistsDNA synthesis inhibitors
TargetsPyrimidines
Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsBiliary Tract Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNucana Biomed
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of LiverpoolNucana Plc
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsPancreatic NeoplasmsBiliary Tract Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A